chevron_leftBack
As of 14 June 2026, Protagenic Therapeutics, Inc. has a market cap of $1.59M USD, ranking #47659 globally and #6076 in the United States.
It ranks #4225 in the Healthcare sector, and #1336 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$1.59MUSD
Enterprise Value
$3.38MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
3
Founded
2004
Website
phytanix.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 11% | 96% | 108% | 98% | -64% | -86% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
PTIX
Protagenic Therapeutics Inc
ISIN: US74365N3017
Shares Out.:
Shares Outstanding:
1.81M1
Shares Float:
1.729M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.08 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Protagenic Therapeutics, Inc.
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
48M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
34M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
23M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
17M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
9M%
|
19.5
|
|
NYSE: BMY
|
$117.58B
7M%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
20M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
18M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
17M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
11M%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
7M%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
7M%
80.96B GBP
|
14.6
|
chevron_leftBack